echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Potential "first-in-class" targeted protein degradation agents enter the clinic

    Potential "first-in-class" targeted protein degradation agents enter the clinic

    • Last Update: 2021-10-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On October 6, 2021, Dialectic Therapeutics announced that the first-generation compound DT2216, constructed based on its proprietary new anti-apoptotic protein targeted degradation technology (APTaD), has completed the first patient administration in a phase 1 clinical trial.


    Preclinical studies have shown that DT2216 can selectively induce the degradation of BCL-XL protein in cancer cells


    Picture source: reference [2]

    This multi-center, dose-escalating phase 1 clinical trial is aimed at patients with advanced/metastatic solid tumors and hematological malignancies, who no longer respond to approved or standard treatments


    Reference materials:

    [1] Dialectic Therapeutics Announces First-in-Human Dose in Phase 1 Clinical Trial Evaluating DT2216, its First Generation Antiapoptotic Protein Targeted Degradation (APTaD™) Compound, in Patients with Relapsed or Refractory Malignancies.


    [2] Pal, P.


    (The original text has been deleted)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.